The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.57BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Revenue (TTM)
2.27BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Profit Margin
-0.93%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Beta
1.40x
vs all stocks
Updated Sep 28, 2026
52-Week Change
-5.23%
vs all stocks
Updated Sep 28, 2026
Market Capitalization
5.57BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Enterprise Value
7.33BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Forward P/E
79.84x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Price to Sales (TTM)
2.46x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Price to Book (MRQ)
5.08x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Enterprise to Revenue
3.23x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Enterprise to EBITDA
26.53x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 20.16×.Updated Sep 28, 2026
Gross Margin
14.14%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 17.28%.Updated Sep 28, 2026
Profit Margin
-0.93%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Operating Margin
7.89%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Return on Assets (TTM)
1.70%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Return on Equity (TTM)
1.50%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Revenue (TTM)
2.27BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Revenue per Share (TTM)
29.52USDUpdated Sep 28, 2026
Quarterly Revenue Growth
25.00%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Gross Profit (TTM)
392.17MUSD
vs all stocks (USD)
Updated Sep 28, 2026
EBITDA (TTM)
363.40MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Net Income (TTM)
-21.12MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Quarterly Earnings Growth (YoY)
-47.90%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Operating Cash Flow (TTM)
310.06MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Levered Free Cash Flow (TTM)
157.74MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Sep 28, 2026
Payout Ratio
0.00%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Minority Interest (Equity)
266.00MUSDFY2025 · Dec 31, 2025
Revenue
2.04BUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
1.80BUSDFY2025 · Dec 31, 2025
Gross Profit
235.49MUSDFY2025 · Dec 31, 2025
Operating Income
83.36MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
31.91MUSDFY2025 · Dec 31, 2025
Income Tax Expense
14.86MUSDFY2025 · Dec 31, 2025
Net Income
17.05MUSDFY2025 · Dec 31, 2025
EBIT
101.82MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
342.29MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
69.91MUSDFY2025 · Dec 31, 2025
EPS (Basic)
-0.2500USDFY2025 · Dec 31, 2025
EPS (Diluted)
-0.2500USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
75.19MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
75.19MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
17.05MUSDFY2025 · Dec 31, 2025
Minority Interests (P&L)
-35.70MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
285.58MUSDFY2025 · Dec 31, 2025
Free Cash Flow
73.62MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
767.22MUSDFY2025 · Dec 31, 2025
Interest Paid
72.27MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
17.05MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
211.99MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
54.60MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
11.69MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-9.56MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
52.42MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-52.61MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-211.96MUSDFY2025 · Dec 31, 2025
Net Acquisitions
-137.57MUSDFY2025 · Dec 31, 2025
Other Investing Activity
5.67MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-343.87MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
99.00MUSDFY2025 · Dec 31, 2025
Long-term Debt Payments
-27.78MUSDFY2025 · Dec 31, 2025
Other Financing Charges
-4.46MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
66.76MUSDFY2025 · Dec 31, 2025
Shares Outstanding
78.65MSharesUpdated Sep 28, 2026
Float Shares
65.76MSharesUpdated Sep 28, 2026
Shares Short
9.67MSharesUpdated Sep 28, 2026
Short Ratio
14.49days
vs all stocks
Updated Sep 28, 2026
Short % of Shares Outstanding
14.54%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 12.3%.Updated Sep 28, 2026
% Held by Insiders
9.96%
vs all stocks
Updated Sep 28, 2026
% Held by Institutions
105.39%
vs all stocks
Updated Sep 28, 2026
Total Cash (MRQ)
726.27MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Total Cash per Share (MRQ)
9.23USDUpdated Sep 28, 2026
Total Debt (MRQ)
2.18BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Total Debt to Equity (MRQ)
1.57x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Current Ratio (MRQ)
1.48x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Book Value per Share (MRQ)
13.94USDUpdated Sep 28, 2026
Total Assets
3.76BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.03BUSDFY2025 · Dec 31, 2025
Total Liabilities
2.40BUSDFY2025 · Dec 31, 2025
Total Non-current Assets
2.73BUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.82BUSDFY2025 · Dec 31, 2025
Total Current Liabilities
586.76MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
767.22MUSDFY2025 · Dec 31, 2025
Accounts Receivable
200.32MUSDFY2025 · Dec 31, 2025
Accounts Payable
153.23MUSDFY2025 · Dec 31, 2025
Short-term Debt
87.36MUSDFY2025 · Dec 31, 2025
Deferred Revenue
7.27MUSDFY2025 · Dec 31, 2025
Long-term Debt
1.77BUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
22.52MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
8.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
-95.44MUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.36BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
50.82USDUpdated Sep 28, 2026
52-Week High
85.84USDUpdated Sep 28, 2026
52-Week Change
-5.23%
vs all stocks
Updated Sep 28, 2026
Beta
1.40x
vs all stocks
Updated Sep 28, 2026
50-Day MA
71.56USDUpdated Sep 28, 2026
200-Day MA
65.63USDUpdated Sep 28, 2026
Avg 10-Day Volume
930.66KSharesUpdated Sep 28, 2026
Avg 30-Day Volume
706.29KSharesUpdated Sep 28, 2026
Diluted EPS (TTM)
-0.2600USDUpdated Sep 28, 2026
Other Income / Expense
18.46MUSDFY2025 · Dec 31, 2025
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Cash-Backed Growth Configuration
Revenue has grown steadily, and the cash arriving matches reported profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 14.1%, lower than 95% of its Diagnostics & Research peers (median 38.5%)Significant